Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- OKTA +14% (also announces milestone related to AWS), SE +9.6%, GENI +9.4%, ESPR +7%, ONON +6.8%, DAVE +5.3%, OLPX +4.3%, HSII +4%, NFE +2.3%, NATL +0.8%, TGT +0.5%
Other news:
- CAPR +15.2% (FDA has accepted for review its Biologics License Application seeking full approval for deramiocel, an investigational cell therapy)
- SNV +10.7% (increases dividend)
- BWMX +4.1% (appoints new CFO)
- ONC +3.2% (receives FDA approval for TEVIMBRA in combination with chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma)
- PAAS +1.5% (NCIB renewal)
- AIR +1.4% (adds distribution support)
- ANIP +1.2% (FDA approval of Purified Cortrophin Gel)
- HAE +1.1% (appoints new COO)